New combo therapy aims to deepen remissions in Tough-to-Treat myeloma

This study tests whether adding a drug called cevostamab after standard CAR T cell therapy can help people with relapsed or refractory multiple myeloma achieve deeper, longer-lasting remission. About 30 adults who have already received CAR T cells will receive cevostamab infusions every three weeks for up to eight cycles. The main goal is to see if more participants become cancer-free at the cellular level (MRD-negative) one year after treatment.